Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ClinicalTrials.gov 24,857 recruiting now free trial finder

Find a clinical trial that's recruiting now

Search 24,857 actively recruiting US clinical trials by condition, drug, or state, each entry links straight to its NIH ClinicalTrials.gov record so you can check eligibility and contact the study team.

24,857
trials recruiting now
14%
of all US trials open to enrollment
52
states with recruiting sites

A trial is listed as recruiting when its sponsor has marked it open to new participants on the public registry. Type a condition or drug name (for example, "breast cancer" or "pembrolizumab") to narrow the list, and add a state to find studies with a site near you. Results are ordered with the most relevant recruiting studies first; each card shows the study phase and enrollment target, and opens the full record, including eligibility criteria and contact details, on ClinicalTrials.gov.

100 trials found

Recruiting 999,999 target

Molecular Genetics Studies of Cancer Patients and Their Relatives

City of Hope Medical Center

NCT04185935

Recruiting 80,000 target

Generic Database of Very Low Birth Weight Infants

NICHD Neonatal Research Network

NCT00063063

Recruiting 68,000 target

Follow-up Visit of High Risk Infants

NICHD Neonatal Research Network

NCT00009633

Recruiting 47,500 target

Total Cancer Care Protocol: A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer

New Mexico Cancer Research Alliance

NCT03977402

Recruiting 20,000 target

A Prospective Registry to Enable Collection of Standardized Routine Care Oncology Patient Data

N-Power Medicine

NCT06877884

Recruiting 20,000 target

De-identified UNMH EEG Corpus Database Creation With Fully De-identified Clinical Information

University of New Mexi

NCT05140265

Recruiting Phase 4 10,742 target

Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL

Ohio State University

NCT06468202

Recruiting 5,000 target

The Society for Obstetric Anesthesia and Perinatology Research Network General Anesthesia Registry

Yale University

NCT06030063

Recruiting Phase 3 4,000 target

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49

Vaxcyte

NCT07284654

Recruiting 3,600 target

DISCOVERY of Risk Factors for Type 2 Diabetes in Youth

George Washington University

NCT06525259

Recruiting Phase 3 2,540 target

CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes

VA Office of Research and Development

NCT05931276

Recruiting NA 2,433 target

Neonatal Platelet Transfusion Threshold Trial

NICHD Neonatal Research Network

NCT06676904

Recruiting 1,600 target

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

Duke University

NCT03511118

Recruiting Phase 4 1,572 target

DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes

Ohio State University

NCT06445946

Recruiting 1,500 target

International Multicentric Observational Study to Characterize Subpopulations of Patients With Autism Spectrum Disorder

Stalicla

NCT05590715

Recruiting NA 1,400 target

End-Tidal Oxygen for Intubation in the Emergency Department

Sydney Local Health District

NCT06578468

Recruiting Phase 3 1,300 target

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Kura Oncology

NCT07007312

Recruiting Phase 3 1,300 target

Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)

NYU Langone Health

NCT04474223

Recruiting Phase 2 1,050 target

CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial

Jason Sperry

NCT05958342

Recruiting NA 1,001 target

Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing

New Mexico Cancer Research Alliance

NCT06207864

Recruiting Phase 3 1,000 target

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Merck Sharp & Dohme

NCT07060807

Recruiting Phase 3 1,000 target

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Bristol-Myers Squibb

NCT06561386

Recruiting Phase 3 1,000 target

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Olema Pharmaceuticals

NCT07085767

Recruiting NA 1,000 target

Treatment of Brain AVMs (TOBAS) Study

Centre hospitalier de l'Université de Montréal (CHUM)

NCT02098252

Recruiting Phase 3 1,000 target

Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children

Philip Spinella

NCT06070350

Recruiting Phase 3 851 target

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

Merck Sharp & Dohme

NCT06422143

Recruiting Phase 2 827 target

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

Gilead Sciences

NCT03547973

Recruiting Phase 3 800 target

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Eli Lilly and Company

NCT07369011

Recruiting 796 target

Target Trial Emulation for Pharmacologic Treatment of Neonatal Opioid Withdrawal Syndrome

HELP for NOWS Consortium

NCT07278375

Recruiting Phase 3 777 target

Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy

SWOG Cancer Research Network

NCT05642611

Recruiting Phase 3 770 target

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Merck Sharp & Dohme

NCT06824467

Recruiting 760 target

Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)

Zimmer Biomet

NCT05787821

Recruiting Phase 3 750 target

A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis

Janssen Research & Development

NCT06807424

Recruiting Phase 3 750 target

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Amgen

NCT05920356

Recruiting NA 750 target

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01)

National Cancer Institute (NCI)

NCT06498661

Recruiting Phase 3 720 target

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination

Vaxcyte

NCT07425392

Recruiting NA 698 target

Suicide in Urban Natives: Detection and Networks to Combat Events

University of Colorado, Denver

NCT03136094

Recruiting Phase 3 695 target

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

Gilead Sciences

NCT06801834

Recruiting Phase 3 686 target

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

Merck Sharp & Dohme

NCT06459180

Recruiting Phase 3 600 target

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Hoffmann-La Roche

NCT06793215

Recruiting NA 600 target

Comparing Telephone Symptom Monitoring Interventions for Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment

NRG Oncology

NCT06279013

Recruiting Phase 3 550 target

A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Neurocrine Biosciences

NCT07196501

Recruiting Phase 3 530 target

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Bristol-Myers Squibb

NCT06646276

Recruiting Phase 2 501 target

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Karyopharm Therapeutics

NCT04442022

Recruiting 500 target

American Indian Chronic Renal Insufficiency Cohort Study (AI-CRIC Study)

University of New Mexi

NCT04185844

Recruiting NA 500 target

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)

National Cancer Institute (NCI)

NCT07281430

Recruiting 500 target

Collection of Sputum and Labeling for Lung Cancer

bioAffinity Technologies

NCT03457415

Recruiting Phase 3 500 target

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Johnson & Johnson Enterprise Innovation

NCT04892173

Recruiting Phase 3 500 target

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

Merus B.V.

NCT06525220

Recruiting Phase 2 480 target

Psilocybin for Opioid Use Disorder (OUD)

NYU Langone Health

NCT06796062

Recruiting Phase 3 462 target

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

Novartis Pharmaceuticals

NCT05126277

Recruiting Phase 1 460 target

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

AstraZeneca

NCT05123482

Recruiting Phase 2 454 target

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

AstraZeneca

NCT05489211

Recruiting Phase 3 444 target

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Amgen

NCT06700343

Recruiting Phase 2 440 target

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Exelixis

NCT06943755

Recruiting Phase 4 432 target

Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence

Women and Infants Hospital of Rhode Island

NCT05806164

Recruiting NA 425 target

Evaluation of Potassium (K) and Ionized Calcium (iCa) Tests Using Capillary Specimens

Abbott Point of Care

NCT07287618

Recruiting NA 425 target

Clinical Evaluation of Precision for the Potassium and Ionized Calcium Tests in Capillary Specimens

Abbott Point of Care

NCT07287631

Recruiting NA 424 target

Technology Assisted Collaborative Care Intervention to Improve Patient-centered Outcomes in Dialysis Patients

University of Pittsburgh

NCT06978127

Recruiting Phase 2 410 target

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Inhibrx Biosciences

NCT06295731

Recruiting NA 407 target

Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System

Boston Scientific Corporation

NCT06735534

Recruiting NA 402 target

SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers

Beth Israel Deaconess Medical Center

NCT06896474

Recruiting Phase 3 400 target

A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo

Pfizer

NCT06163326

Recruiting 400 target

Transformative Research in Diabetic Nephropathy

University of Pennsylvania

NCT02986984

Recruiting Phase 1 400 target

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

Janssen Research & Development

NCT04811560

Recruiting 400 target

Wearable Spine Health System for Military Readiness

Ohio State University

NCT05944354

Recruiting 400 target

BostonGene and Exigent Genomic INsight Study

BostonGene

NCT06272864

Recruiting Phase 1 392 target

A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

UCB Biopharma SRL

NCT07290036

Recruiting Phase 2 380 target

Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare

Atom Therapeutics Co.

NCT07145229

Recruiting Phase 2 360 target

A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

Vicore Pharma AB

NCT06588686

Recruiting Phase 3 360 target

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Novartis Pharmaceuticals

NCT06846281

Recruiting Phase 4 358 target

Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis

VA Office of Research and Development

NCT04373317

Recruiting Phase 2 350 target

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

BioNTech SE

NCT04534205

Recruiting 350 target

Assessment of Support With Impella® Best Practices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Abiomed

NCT06964685

Recruiting 334 target

Neurocognitive Abnormalities in Stimulant Abuse Among High-Risk Women

The Mind Research Network

NCT05845333

Recruiting NA 334 target

Distal Radius Interventions for Fracture Treatment

Ann & Robert H Lurie Children's Hospital of Chicago

NCT05131685

Recruiting Phase 3 316 target

Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial

NICHD Neonatal Research Network

NCT06679855

Recruiting Phase 2 315 target

A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)

Merck Sharp & Dohme

NCT07133633

Recruiting Phase 1 312 target

A Study of YL201 in Patients With Advanced Solid Tumors

MediLink Therapeutics (Suzhou) Co.

NCT05434234

Recruiting Phase 2 300 target

A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder

Eli Lilly and Company

NCT06817356

Recruiting NA 300 target

Desara ® One Single Incision Sling 522 Study

Caldera Medical

NCT04772131

Recruiting Phase 2 290 target

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Merck Sharp & Dohme

NCT05139017

Recruiting NA 288 target

Matching Treatments to Cognitive Deficits in Offenders With Substance Use Disorders

The Mind Research Network

NCT06981351

Recruiting Phase 3 276 target

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

Ipsen

NCT06016842

Recruiting Phase 2 270 target

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Corcept Therapeutics

NCT06906341

Recruiting Phase 1 270 target

Study of LYL314 in Aggressive Large B-Cell Lymphoma

Lyell Immunopharma

NCT05826535

Recruiting Phase 3 264 target

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

Alebund Pharmaceuticals

NCT06933472

Recruiting NA 252 target

Incremental Hemodialysis for Veterans in the First Year of Dialysis (IncHVets)

VA Office of Research and Development

NCT05465044

Recruiting Phase 1 252 target

A Clinical Study of YL205 in Patients With Advanced Solid Tumors

MediLink Therapeutics (Suzhou) Co.

NCT06459973

Recruiting 250 target

Longitudinal Studies to Identify Biomarkers for Sturge-Weber Syndrome

University of Illinois at Chicago

NCT04717427

Recruiting NA 244 target

Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy

Wake Forest University Health Sciences

NCT05703269

Recruiting Phase 1 242 target

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

VM Oncology

NCT03556228

Recruiting NA 240 target

WEAVE NM: Heart Health and Nutrition for Life

University of New Mexi

NCT07074145

Recruiting Phase 3 236 target

Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)

VistaGen Therapeutics

NCT06615557

Recruiting NA 232 target

Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System

DT MedTech

NCT04770870

Recruiting Phase 4 230 target

Particulate vs. Non-Particulate Steroid for Sacroiliac Joint Injection

University of New Mexi

NCT06268704

Recruiting Phase 3 220 target

64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer

Clarity Pharmaceuticals

NCT06970847

Recruiting Phase 2 218 target

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Astellas Pharma Global Development

NCT07005154

Recruiting NA 200 target

Carbon Dioxide Administration and Brain Waste Clearance

Andrew Mayer

NCT07357090

Recruiting 200 target

An Observational Study of Individuals With Isolated Dystonia

Vima Therapeutics

NCT07111663

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Recruiting status is reported by each study's sponsor and mirrored from the public registry. Always confirm current eligibility and status on ClinicalTrials.gov before contacting a study.

Verify with NIH →